PCIF1 knockdown makes CRC tumors more sensitive to anti-PD-1 therapy by increasing the population of natural killer cells and decreasing that of monocytic myeloid-derived suppressor cells in the tumor microenvironment. Here, PCIF1 is linked to neoplasm.